Valeant Pharmaceuticals Revenues And Revenue Growth From 2012 To 2016

This report provides the last five years revenues and revenue growth of Valeant Pharmaceuticals International, Inc. (VRX) from 2012 to 2016. Valeant Pharmaceuticals generated a total of $9.7 billion revenues during 2016. Valeant Pharmaceuticals reported a revenue growth of -7.4% year-over-year during 2016. The revenues and the revenue growth correspond to the fiscal year ending in December.

Valeant Pharmaceuticals Revenues From 2012 To 2016

Here are the revenues and the revenue growth details of Valeant Pharmaceuticals during the last five years:

  • Valeant Pharmaceuticals generated a total of $3.5 billion revenues during 2012. Valeant Pharmaceuticals reported a revenue growth of 43.4% year-over-year during 2012.
  • Valeant Pharmaceuticals generated a total of $5.8 billion revenues during 2013. Valeant Pharmaceuticals reported a revenue growth of 65.8% year-over-year during 2013.
  • Valeant Pharmaceuticals generated a total of $8.2 billion revenues during 2014. Valeant Pharmaceuticals reported a revenue growth of 42.2% year-over-year during 2014.
  • Valeant Pharmaceuticals generated a total of $10.4 billion revenues during 2015. Valeant Pharmaceuticals reported a revenue growth of 27.3% year-over-year during 2015.
  • Valeant Pharmaceuticals generated a total of $9.7 billion revenues during 2016. Valeant Pharmaceuticals reported a revenue growth of -7.4% year-over-year during 2016.

Why Analyze Revenue Growth?

Revenue growth is the most commonly analyzed financial metric. Revenue Growth is the percent increase (or decrease) of a company's revenue between two time periods. It is computed by using the following formula: ((revenues during the time period two - revenues during the time period one) / revenues during the time period one)*100. If the time periods are two consecutive years, then the revenue growth is referred to as the annual revenue growth year-over-year. If the time periods are two consecutive quarters, then the revenue growth is referred to as the quarterly revenue growth quarter-over-quarter. If the time periods refer to the same quarter in the two consecutive years, then the revenue growth is referred to as quarterly revenue growth year-over-year. In case the time periods are two non-consecutive years, then the revenue CAGR (Commutative Annual Growth Rate) is computed.

Revenue growth analysis is important for a number of reasons. First, it helps in understanding how a business is performing. If the revenue growth rates are positive, it means the business is performing well and the revenues are increasing. If the revenue growth rates are negative, it means the revenues are declining and the company needs to take measures to increase them. If they don't, the company will continue to shrink. Second, a company's historical revenue growth analysis along with the market size and market share analysis helps in forecasting the future revenues of a company. Third, a comparison of a company's growth rates with its competitors helps in determining who is winning more business. A revenue growth higher than the industry average translates into increasing market share. Companies with very high revenue growth rates have the potential to be the industry disrupters.

Valeant Pharmaceuticals Ranking

With $9.7 billion revenues, Valeant Pharmaceuticals ranked number 299 in the R&P Research list of top-3000 public companies in the US by revenues during 2016. Each one of the top-3000 companies generated more than $50 million of annual revenues during 2016.

The top-20 companies in the US by revenues during 2016 were:

  1. Walmart ($482.1 billion)
  2. ExxonMobil ($226.1 billion)
  3. Berkshire Hathaway ($223.6 billion)
  4. Apple ($215.6 billion)
  5. McKesson ($190.9 billion)
  6. UnitedHealth Group ($184.8 billion)
  7. CVS Health ($177.5 billion)
  8. General Motors ($166.4 billion)
  9. AT&T ($163.8 billion)
  10. Ford Motor ($151.8 billion)
  11. AmerisourceBergen ($146.8 billion)
  12. Amazon ($136 billion)
  13. Verizon ($126 billion)
  14. General Electric ($123.7 billion)
  15. Cardinal Health ($121.5 billion)
  16. Costco ($118.7 billion)
  17. Walgreens Boots Alliance ($117.4 billion)
  18. Chevron ($114.5 billion)
  19. Kroger ($109.8 billion)
  20. Express Scripts Holding ($100.3 billion)

For the purpose of performance benchmarking of a company with a sector or industry average, R&P Research associates every company with one sector and one industry. An industry consists of companies with related/similar business models. A sector comprises of a group of related/similar industries. For high-level analysis purposes, related/similar sectors are grouped into sector groups.

For example, Healthcare sector group is comprised of Life Sciences sector and Healthcare Services sector. Life Sciences sector is comprised of following industries: Pharmaceuticals; Medical Devices; Biotechnology; Diagnostics & Scientific Instruments. Healthcare Services sector is comprised of following industries: Drug Stores, PBM and Distributors; Healthcare Payers; Healthcare Providers; Medical Software; Healthcare Research Services.

Valeant Pharmaceuticals is associated with Healthcare Sector Group, Life Sciences Sector, and Pharmaceuticals Industry.

With $9.7 billion revenues, Valeant Pharmaceuticals ranked number 42 of all the companies in the US Healthcare sector group. There were a total of 290 public companies in the US Healthcare sector group that had revenues greater than $50 million during 2016.

The top-10 companies in the US Healthcare sector group by revenues during 2016 were:

  1. McKesson ($190.9 billion)
  2. UnitedHealth Group ($184.8 billion)
  3. CVS Health ($177.5 billion)
  4. AmerisourceBergen ($146.8 billion)
  5. Cardinal Health ($121.5 billion)
  6. Walgreens Boots Alliance ($117.4 billion)
  7. Express Scripts Holding ($100.3 billion)
  8. Anthem ($84.9 billion)
  9. J&J ($71.9 billion)
  10. Aetna ($63.2 billion)

Healthcare sector group is comprised of the following sectors: Life Sciences; Healthcare Services.

With $9.7 billion revenues, Valeant Pharmaceuticals ranked number 20 of all the companies in the US Life Sciences sector. There were a total of 197 public companies in the US Life Sciences sector that had revenues greater than $50 million during 2016.

The top-10 companies in the US Life Sciences sector by revenues during 2016 were:

  1. J&J ($71.9 billion)
  2. Pfizer ($52.8 billion)
  3. Merck ($39.8 billion)
  4. Gilead Sciences ($30.4 billion)
  5. Medtronic ($28.8 billion)
  6. Abbvie ($25.6 billion)
  7. Amgen ($23 billion)
  8. Eli Lilly ($21.2 billion)
  9. Abbott Laboratories ($20.9 billion)
  10. Bristol Myers Squibb ($19.4 billion)

Life Sciences sector is comprised of the following industries: Pharmaceuticals; Medical Devices; Biotechnology; Diagnostics & Scientific Instruments. The definitions for each of the industries is as follows:

  • Pharmaceuticals industry includes companies that discover, develop, manufacture, and market medicines licensed for use as medications. In general these companies offer pharmaceutical products that can be described as prescription or over-the-counter medicines. Many Pharmaceutical companies also offer a diverse portfolio of animal health products, services and solutions. Many diversified pharmaceutical companies operate in more than two operating segments like consumer health products, medical devices and pharmaceutical.
  • Medical Devices industry includes manufacturers and distributors of medical equipments and medical supplies. Medical equipments include large scale capital equipmets such as X-Ray machines and MRI scanners and other nondisposable medical devices like stents and pacemakers. Medical supplies include makers of contact lenses, eyeglass lenses, bandages and other disposable products.
  • Biotechnology industry includes Biotechnology product companies, subscription companies, and service companies. Biotechnology product companies offer pharmaceutical drug products that are manufactured in, extracted from, or semi synthesized from biological sources. Subscription-based companies develop genome databases, which can be used to develop medicinal drugs. Service companies offer solutions based on a common technology or generic tool of other large pharmaceutical or biopharmaceutical companies.
  • Diagnostics & Scientific Instruments industry includes companies that provide testing products, diagnostic reagents, instruments and diagnostic services to aid in the detection and treatment of a wide range of diseases. It also includes molecular diagnostic and genetic testing companies that develop, manufacture, market and provide diagnostic tests, diagnostic systems and related products and services. Also included are companies that manufacture and market analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics.

With $9.7 billion revenues, Valeant Pharmaceuticals ranked number 10 of all the companies in the US Pharmaceuticals industry. There were a total of 49 public companies in the US Pharmaceuticals industry that had revenues greater than $50 million during 2016.

The top-10 companies in the US Pharmaceuticals industry by revenues during 2016 were:

  1. J&J ($71.9 billion)
  2. Pfizer ($52.8 billion)
  3. Merck ($39.8 billion)
  4. Eli Lilly ($21.2 billion)
  5. Abbott Laboratories ($20.9 billion)
  6. Bristol Myers Squibb ($19.4 billion)
  7. Allergan ($14.6 billion)
  8. Shire ($11.4 billion)
  9. Mylan ($11.1 billion)
  10. Valeant Pharmaceuticals ($9.7 billion)

Companies Segmentation

To identify and analyze high/low growth or most/least profitable similar-size companies in different sectors or industries, R&P research classifies all companies into different segments based upon their revenues, revenue growth, and net profit margins.

Based upon their annual revenues, the companies are classified into one of the following four segments:

  1. Mega companies, having revenues greater than $50 billion.
  2. Very Large companies, having revenues between $10 billion and $50 billion.
  3. Large companies, having revenues between $1 billion and $10 billion.
  4. Mid-size companies, having revenues between $50 million and $1 billion.

With $9.7 billion revenues, Valeant Pharmaceuticals was in the Large companies revenue segment during 2016. There were a total of 1097 companies in the Large companies revenue segment during 2016.

Based upon their annual revenue growth, the companies are classified into one of the following eight segments:

  1. Very High positive growth companies, having annual revenue growth greater than 50%.
  2. High positive growth companies, having annual revenue growth between 20% and 50%.
  3. Medium positive growth companies, having annual revenue growth between 5% and 20%.
  4. Low positive growth companies, having annual revenue growth between 0% and 5%.
  5. Low negative growth companies, having annual revenue growth between -5% and 0%.
  6. Medium negative growth companies, having annual revenue growth between -20% and -5%.
  7. High negative growth companies, having annual revenue growth between -50% and -20%.
  8. Very High negative growth companies, having annual revenue growth less than -50%.

With -7.4% revenue growth year-over-year, Valeant Pharmaceuticals was in the Medium negative revenue growth segment during 2016. There were a total of 448 companies in the Medium negative revenue growth segment during 2016. Of the US top-3000 companies, 1985 (nearly two-third of the total) had positive revenue growth and 1015 (nearly one-third of the total) had negative revenue growth during 2016.

Based upon their annual net profit margin, the companies are classified into one of the following eight segments:

  1. Very High positive margin companies, having net profit margin greater than 50%.
  2. High positive margin companies, having net profit margin between 20% and 50%.
  3. Medium positive margin companies, having net profit margin between 5% and 20%.
  4. Low positive margin companies, having net profit margin between 0% and 5%.
  5. Low negative margin companies, having net profit margin between -5% and 0%.
  6. Medium negative margin companies, having net profit margin between -20% and -5%.
  7. High negative margin companies, having net profit margin between -50% and -20%.
  8. Very High negative margin companies, having net profit margin less than -50%.

With a net margin of -24.9%, Valeant Pharmaceuticals was in the High negative net profit margin segment during 2016. There were a total of 155 companies in the High negative net profit margin segment during 2016. Of the US top-3000 companies, 2244 (nearly three-fourth of the total) had positive net profit margin and 756 (nearly one-fourth of the total) had negative net profit margin during 2016.

Company Business Summary

Valeant Pharmaceuticals International, Inc. operates as a pharmaceutical and medical device company worldwide. It operates in three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The company offers Lotemax gel for the treatment of inflammation and pain following ocular surgery; Ocuvite, a lutein eye vitamin and mineral supplement; PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus products; Biotrue multi-purpose solution for healthy contact lens wear; Artelac to treat dry eyes; Boston, a cleansing solution for gas permeable contact lenses; and Bedoyecta, a vitamin B complex. It also provides SofLens daily disposable contact lenses; ophthalmic surgical products; PureVision, a silicone hydrogel; Biotrue ONEday daily disposable contact lenses; Bausch + Lomb Ultra, a silicone hydrogel replacement contact lens; and medical device systems. In addition, the company offers Xifaxan for the treatment of irritable bowel syndrome; Provenge for the treatment of prostate cancer; Uceris to get ulcerative colitis under control; Arestin, a subgingival sustained-release antibiotic; Jublia for the treatment of onychomycosis; Solodyn for the treatment of acne; Elidel to treat skin conditions; and Glumetza tablets to enhance glycemic control. Further, it provides Wellbutrin XL for the treatment of major depressive disorder; Isuprel injections; Xenazine for the treatment of chorea; Nitropress for the reduction of blood pressure of patients in hypertensive crises; Cuprimine to treat Wilson's disease; Zegerid to treat certain stomach and esophagus problems; Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; and Latanoprost medicines to treat a type of glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. The company was founded in 1983 and is headquartered in Laval, Canada.

Data Source

The chart and the data on this page are sourced from the R&P Research Industry Intelligence Platform. The platform provides the key financial metrics for all the public companies in the United States. The platform empowers users to compare last five or 15 years financial data of a company with the other companies or the industry averages. This benchmarking exercise yields powerful insights that can drive better business decisions.


Industry Peers and Competitors of Valeant Pharmaceuticals

Allergan (AGN) Business Analysis – Analyze Historical Performance, Strategic Priorities, And...

Allergan Plc with $15 billion revenues in the year 2016 was the number 7 Pharmaceuticals company. Read this report to know the top competitors of Allergan and identify growth and cost optimization opportunities of Allergan

Shire (SHPG) Business Analysis – Analyze Historical Performance, Strategic Priorities, And...

Shire Plc with $11 billion revenues in the year 2016 was the number 8 Pharmaceuticals company. Read this report to know the top competitors of Shire and identify growth and cost optimization opportunities of Shire

Mylan (MYL) Business Analysis – Analyze Historical Performance, Strategic Priorities, And...

Mylan N.V. with $11 billion revenues in the year 2016 was the number 9 Pharmaceuticals company. Read this report to know the top competitors of Mylan and identify growth and cost optimization opportunities of Mylan

Zoetis (ZTS) Business Analysis – Analyze Historical Performance, Strategic Priorities, And...

Zoetis Inc. with $5 billion revenues in the year 2016 was the number 11 Pharmaceuticals company. Read this report to know the top competitors of Zoetis and identify growth and cost optimization opportunities of Zoetis

Endo International (ENDP) Business Analysis – Analyze Historical Performance, Strategic Priorities,...

Endo International Plc with $4 billion revenues in the year 2016 was the number 12 Pharmaceuticals company. Read this report to know the top competitors of Endo International and identify growth and cost optimization opportunities of Endo International

Mallinckrodt (MNK) Business Analysis – Analyze Historical Performance, Strategic Priorities, And...

Mallinckrodt Plc with $3 billion revenues in the year 2016 was the number 13 Pharmaceuticals company. Read this report to know the top competitors of Mallinckrodt and identify growth and cost optimization opportunities of Mallinckrodt

Revenues Analysis

Valeant Pharmaceuticals (VRX) Revenues And Revenue Growth From 2012 To 2016

This report provides the last five years revenues and revenue growth of Valeant Pharmaceuticals International, Inc. (VRX) from 2012 to 2016. Valeant Pharmaceuticals generated a total of $9.7 billion revenues during 2016. Valeant Pharmaceuticals reported a revenue growth of -7.4% year-over-year during 2016. The revenues and the revenue growth correspond to the fiscal year ending in December.

Valeant Pharmaceuticals (VRX) Revenues And Revenue Growth From 2002 To 2016

This report provides the last fifteen years revenues and revenue growth of Valeant Pharmaceuticals International, Inc. (VRX) from 2002 to 2016. Valeant Pharmaceuticals generated a total of $9.7 billion revenues during 2016. Valeant Pharmaceuticals reported a revenue growth of -7.4% year-over-year during 2016. The revenues and the revenue growth correspond to the fiscal year ending in December.

Valeant Pharmaceuticals (VRX) Revenue Growth Comparison With Industry Growth From 2012...

This report provides a comparison of Valeant Pharmaceuticals International, Inc. (VRX) revenue growth with Pharmaceuticals industry growth during the last five years from 2012 to 2016. Valeant Pharmaceuticals reported a revenue growth of -7.4% year-over-year during 2016. The Pharmaceuticals industry growth was 7.7% year-over-year during 2016. Valeant Pharmaceuticals growth was slower than the industry during 2016.

Profit Analysis

Valeant Pharmaceuticals (VRX) Net Profit And Net Margin From 2014 To...

This report provides the last three years net profit and net margin of Valeant Pharmaceuticals International, Inc. (VRX) from 2014 to 2016. Valeant Pharmaceuticals reported a total net income of -$2.4 billion during 2016. Valeant Pharmaceuticals generated a total of $9.7 billion revenues during 2016. Valeant Pharmaceuticals net profit margin was -24.9% during 2016. The net profit and the net profit margin correspond to the fiscal year ending in December.

Valeant Pharmaceuticals (VRX) Net Profit And Net Margin From 2002 To...

This report provides the last fifteen years net profit and net margin of Valeant Pharmaceuticals International, Inc. (VRX) from 2002 to 2016. Valeant Pharmaceuticals reported a total net income of -$2.4 billion during 2016. Valeant Pharmaceuticals generated a total of $9.7 billion revenues during 2016. Valeant Pharmaceuticals net profit margin was -24.9% during 2016. The net profit and the net profit margin correspond to the fiscal year ending in December.

Valeant Pharmaceuticals (VRX) Net Profit Margin Comparison With Industry From 2012...

This report provides a comparison of Valeant Pharmaceuticals International, Inc. (VRX) net profit margin with Pharmaceuticals industry net profit margin during the last five years from 2012 to 2016. Valeant Pharmaceuticals reported a net profit margin of -24.9% during 2016. The Pharmaceuticals industry net profit margin was 15.8% during 2016. Valeant Pharmaceuticals was less profitable than the industry during 2016.

Cost & Expenses Analysis

Valeant Pharmaceuticals (VRX) Cost of Sales (COGS) Analysis From 2012 To...

This report provides the last five years cost of sales (COGS) analysis of Valeant Pharmaceuticals International, Inc. (VRX) from 2012 to 2016. Valeant Pharmaceuticals spent a total of $2.6 billion on COGS during 2016. Valeant Pharmaceuticals generated a total of $9.7 billion revenues during 2016. As a percentage of revenues, Valeant Pharmaceuticals spent 27% of its total revenues on COGS during 2016. The cost of sales (COGS) numbers are for the fiscal year ending in December.

Valeant Pharmaceuticals (VRX) Research & Development (R&D) Spending Analysis From 2012...

This report provides the last five years research and development (R&D) expenses of Valeant Pharmaceuticals International, Inc. (VRX) from 2012 to 2016. Valeant Pharmaceuticals spent a total of $455 million on research and development (R&D) activities during 2016. Valeant Pharmaceuticals generated a total of $9.7 billion revenues during 2016. As a percentage of revenues, Valeant Pharmaceuticals spent 4.7% of its total revenues on R&D activities during 2016. The R&D spending numbers are for the fiscal year ending in December.

Valeant Pharmaceuticals (VRX) Sales, Marketing, General & Administrative (SG&A) Spending Analysis...

This report provides the last five years sales, marketing, general & administrative (SG&A) expenses of Valeant Pharmaceuticals International, Inc. (VRX) from 2012 to 2016. Valeant Pharmaceuticals spent a total of $2.8 billion on sales, marketing, general, and administrative (SG&A) activities during 2016. Valeant Pharmaceuticals generated a total of $9.7 billion revenues during 2016. As a percentage of revenues, Valeant Pharmaceuticals spent 29% of its total revenues on SG&A activities during 2016. The SG&A spending numbers are for the fiscal year ending in December.

Working Capital Analysis

Valeant Pharmaceuticals (VRX) Inventory Spending Analysis From 2012 To 2016

This report provides the last five years inventory spending analysis of Valeant Pharmaceuticals International, Inc. (VRX) from 2012 to 2016. Valeant Pharmaceuticals invested a total of $1.1 billion on inventories during 2016. Valeant Pharmaceuticals generated a total of $9.7 billion revenues during 2016. As a percentage of revenues, Valeant Pharmaceuticals invested 11% of its total revenues on inventories during 2016. The inventory numbers are for the fiscal year ending in December.

Valeant Pharmaceuticals (VRX) Accounts Receivable (A/R) Analysis From 2012 To 2016

This report provides the last five years Accounts Receivable (A/R) analysis of Valeant Pharmaceuticals International, Inc. (VRX) from 2012 to 2016. Valeant Pharmaceuticals invested a total of $2.5 billion on accounts receivable during 2016. Valeant Pharmaceuticals generated a total of $9.7 billion revenues during 2016. As a percentage of revenues, Valeant Pharmaceuticals invested 26% of its total revenues on accounts receivable during 2016. The accounts receivable numbers are for the fiscal year ending in December.

Valeant Pharmaceuticals (VRX) Accounts Payable (A/P) Analysis From 2012 To 2016

This report provides the last five years Accounts Payable (A/P) analysis of Valeant Pharmaceuticals International, Inc. (VRX) from 2012 to 2016. Valeant Pharmaceuticals invested a total of $324 million on accounts payable during 2016. Valeant Pharmaceuticals generated a total of $9.7 billion revenues during 2016. As a percentage of revenues, Valeant Pharmaceuticals invested 3.3% of its total revenues on accounts payable activities during 2016. The accounts payable numbers are for the fiscal year ending in December.

Asset Management Analysis

Valeant Pharmaceuticals (VRX) Property, Plant & Equipment (PP&E) Investment Analysis From...

This report provides the last five years property, plant & equipment (PP&E) investment analysis of Valeant Pharmaceuticals International, Inc. (VRX) from 2012 to 2016. Valeant Pharmaceuticals invested a total of $1.3 billion on property, plant & equipment (PP&E) activities during 2016. Valeant Pharmaceuticals generated a total of $9.7 billion revenues during 2016. As a percentage of revenues, Valeant Pharmaceuticals invested 13.6% of its total revenues on PP&E activities during 2016. The PP&E investment numbers are for the fiscal year ending in December.

Valeant Pharmaceuticals (VRX) Intangible Assets Analysis From 2012 To 2016

This report provides the last five years Intangible assets analysis of Valeant Pharmaceuticals International, Inc. (VRX) from 2012 to 2016. Valeant Pharmaceuticals invested a total of $34.7 billion on Intangible assets during 2016. Valeant Pharmaceuticals generated a total of $9.7 billion revenues during 2016. As a percentage of revenues, Valeant Pharmaceuticals invested 358.5% of its total revenues on intangible assets during 2016. The Intangible asset numbers are for the fiscal year ending in December.

Got Questions?

Get in touch with us. We are happy to help!

Contact Us:


sales@revenuesandprofits.com